Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sym022 in advanced solid tumors or lymphomas
NCT03489369Phase 1Completed
- Sponsor
- Symphogen
- Start
- May 2018
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of Sym022 in solid tumor and lymphoma, sponsored by Symphogen. Primary endpoint: Treatment Related Adverse Events at 19 months. Started May 2018; status: completed.
02
Drugs
Sym022
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT03489369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03489369.